Canopy Growth Corporation completed its acquisition of MTL Cannabis Corp. on March 16, 2026, in a transaction valued at approximately $125 million on a fully‑diluted equity basis and $179 million on an enterprise‑value basis. The deal was financed with the issuance of 41.2 million Canopy shares and a cash payment of C$18.5 million, plus an additional 2,956,391 shares issued to former MTL shareholders under a transfer‑restriction schedule.
The acquisition positions the combined company as Canada’s leading medical‑cannabis platform by revenue. MTL brings a high‑quality flower supply, a network of Canada House clinics, an online marketplace (ABBA Medix), and cultivation facilities in Quebec and Ontario. These assets complement Canopy’s existing Canadian and international operations and provide a platform for growth in regulated markets in Europe and Australia.
Financially, MTL reported net income of $672,884 for the three months ended December 31, 2025, a 155% year‑over‑year increase, underscoring its profitability and cash‑generating nature. Canopy’s recent results show a net revenue of $65.0 million in Q4 FY2025, down 11% YoY, with a gross margin of 16%. The company has reduced debt by $293 million in FY2025 and is targeting $20 million in annualized cost savings, setting the stage for a positive adjusted EBITDA in fiscal 2027.
The transaction is expected to generate approximately $10 million in run‑rate synergies within 18 months. MTL’s management team is being integrated into Canopy’s leadership: former CEO Mike Perron will serve as Chief Operating Officer, while co‑founders Richard and Michel Clément will act as strategic advisors. This integration is intended to strengthen operational execution and accelerate the combined entity’s path to profitability.
"The acquisition of MTL is a defining step forward in strengthening Canopy Growth’s core Canadian business and advancing our path toward sustainable profitability," said Luc Mongeau, CEO of Canopy Growth. "Together we are Canada’s leading medical cannabis company, complemented by a strong and accelerating adult‑use platform," added Richard Clément, co‑founder of MTL Cannabis.
The deal enhances Canopy’s premium flower supply, expands its patient network, and deepens its presence in the medical‑cannabis market. By combining MTL’s cultivation expertise, clinic network, and online marketplace with Canopy’s existing operations, the company is better positioned to capture market share, improve margins, and pursue international expansion, thereby reinforcing its competitive advantage in a consolidating industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.